At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Location: United Kingdom
Employees: 11-50
Total raised: $80M
Founded date: 2019
Investors 5
| Date | Name | Website |
| 29.12.2021 | New Enterp... | nea.com |
| - | F-Prime Ca... | fprimecapi... |
| - | Advent Lif... | adventls.c... |
| - | Life Arc V... | lifearcven... |
| 11.02.2022 | Life Scien... | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.12.2021 | Series A | $80M | - |
Mentions in press and media 23
| Date | Title | Description |
| 16.06.2026 | AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas | • vMiX™ is a vectorized RNA interference (RNAi) platform combining knockdown, cell-specific expression with the flexibility to target multiple genes • Update follows recent positive AVB-406 preclinical data presented at ASGCT, supporting th... |
| 16.06.2026 | AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas | AviadoBio Ltd. (“AviadoBio”), a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, and King’s College London today announced an expanded license agree... |
| 14.05.2026 | AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026 | LONDON – May 14, 2026 – AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced positive preclinical data for the AVB-406 prog... |
| 14.05.2026 | AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026 | AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced positive preclinical data for the AVB-406 program in Alzheimer’s disea... |
| 27.04.2026 | AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid | AviadoBio Ltd. (“AviadoBio”) and Apertura Gene Therapy (“Apertura”), a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced a licensing agreement for Apertura’s TfR1 CapX™, a novel, ... |
| 31.03.2026 | AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial | AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the company has initiated enrollment for the fourth cohort in its... |
| 09.10.2025 | AviadoBio and UgeneX Therapeutics Announce Exclusive Option-License Agreement to Develop Next Generation Optogenetics Gene Therapy to Restore Vision in Patients with Retinal Disease | LONDON, and SHANGHAI – October 9, 2025 – AviadoBio Ltd. (“AviadoBio”), and UgeneX Therapeutics, today announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational, AAV-based ge... |
| 15.05.2025 | AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London | LONDON – May 15, 2025 – AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial i... |
| 01.05.2025 | AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN | LONDON — MAY 1, 2025 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced the completion of the second dose cohort in its... |
| 02.07.2024 | ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center | LONDON — July 1, 2024 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial i... |
Show more